genprowebdirectory
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Insights
Trends for 2020
Trends for 2021
Trends for 2023
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
Subscribe
Login
Contributors
News
Genetic Disease Testing
Multiomics Approach Improves Diagnosis of Rare Disease, Methylmalonic Aciduria
Base Editing
Zinc Finger Design AI Tool Opens Door to Large-Scale Gene Therapies
Cancer
Multidrug Nanoparticle Platform Improves Drug Delivery against Cancer
Cancer
Cancer’s Capacity to Resist Treatment Thwarted
Animal Models
Microbiome and its Metabolites Promote Endometriosis in Animal Model
Insights
All
Trends for 2020
Trends for 2021
Trends for 2023
Artificial Intelligence
Chiral Spectroscopy Lessens the Chiral Resolution Stumbling Block
Antibodies
Advanced Therapies Could Be Sleepwalking into a Manufacturing Cost Crisis
Bioprocessing
Cell and Gene Therapy Scale-Up Challenges
Bioprocessing
Making Molecules Instead of Growing Them
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
A-Lists
Drug Discovery
Seven Biopharma Trends to Watch in 2023
A-Lists
Top 50 NIH-Funded Institutions of 2022
A-Lists
Top 10 U.S. Biopharma Clusters
A-Lists
Top 10 Spatial Biology Companies
A-Lists
Top 25 Biotech Companies of 2022
Magazine
Current Issue
Past Issues
Supplements
Subscribe
Multimedia
Summits
Webinars
Learning Labs
GEN Live
Podcasts
Resources
eBooks/Perspectives
Tutorials
Biotech Briefs
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Best of the Web
Best Apps
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Get GEN Edge
Home
Topics
Cancer
Cancer
Random
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Cancer
Ascenta Enters Deal Potentially Worth $398M with Sanofi-Aventis
Cancer
Halting Translation of Cancer-Promoting Proteins
Cancer
Cancer Runs Slower When Its Clock Is Ticking
Cancer
Enzo to Market GeneNews’ Colorectal Cancer Blood Test in NY and NJ
Cancer
David M. Sabatini, M.D., Ph.D., Wins 2017 Lurie Prize
Cancer
miRagen Secures Exclusive License to In Vivo Applications of t2cure’s miR-92...
Cancer
Approved Anti-Cancer Drugs Reveal New Target: Non-Coding RNAs
Cancer
Genomic Subtyping Offers Promise for Better Diagnosis and Treatment of High-Risk...
Cancer
Novel Immunotherapy Approach Holds Promise for Pediatric Brain Cancer
Cancer
Dr. Reddy’s Buys Ex-Asia Rights to Eisai Cancer Candidate E7777
Cancer
Repurposing an Antiparasitic Drug to Treat Brain Tumors
Cancer
MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up...
Cancer
Genentech to Develop Hanmi Cancer Candidate HM95573
Cancer
Novel Molecular Pathway Involved in the Immunotherapy Response Identified
Cancer
Sanofi-Aventis’ Fibroblast Growth Factor Gene Therapy Fails in Phase III
1
2
3
...
466
Page 1 of 466
Scroll Up
Login
Subscribe
![Firm will initially evaluate miRNA as target for ischemic and vascular disorders.[Sebastian Kaulitzki-Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/UGENWebsitepicturesTopStoriesNov2010Nov30_2010_22200540_PlasmaBloodcellsArteries_miRagenInVivot2curemiR922135299351-324x160.jpg "miRagen Secures Exclusive License to In Vivo Applications of t2cure’s miR-92 IP")
![Humanized anti-CD19 mAb XmAb5574 is in early clinical development against CLL. [© Sebastian Kaulitzki - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/June28_8300503_AntibodiesBlood_MorphoSysXencorAntibodyBcell1253719912-324x160.jpg "MorphoSys Nabs Xencor’s Phase I B-Cell Malignancy Antibody for $13M Up Front")
![Firm still deciding on fate of drug and will present full trial results in November. [© Sebastian Kaulitzki - Fotolia.com]](https://www.genengnews.com/wp-content/uploads/2018/08/Sept23_2010_22200540_PlasmaBloodcellsArteries_SanofiAventisFibroblastDrugFailsPh31124117238-324x160.jpg "Sanofi-Aventis’ Fibroblast Growth Factor Gene Therapy Fails in Phase III")